glucagon has been researched along with 4-iodo-2,5-dimethoxyphenylisopropylamine in 1 studies
Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (4-iodo-2,5-dimethoxyphenylisopropylamine) | Trials (4-iodo-2,5-dimethoxyphenylisopropylamine) | Recent Studies (post-2010) (4-iodo-2,5-dimethoxyphenylisopropylamine) |
---|---|---|---|---|---|
26,039 | 1,498 | 3,054 | 843 | 1 | 127 |
Protein | Taxonomy | glucagon (IC50) | 4-iodo-2,5-dimethoxyphenylisopropylamine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0032 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sugimoto, Y; Yamada, J | 1 |
1 other study(ies) available for glucagon and 4-iodo-2,5-dimethoxyphenylisopropylamine
Article | Year |
---|---|
Effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on plasma glucose and glucagon levels of rats.
Topics: Adrenal Medulla; Amphetamines; Animals; Blood Glucose; Dose-Response Relationship, Drug; Glucagon; Hyperglycemia; Ketanserin; Male; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Ritanserin; Serotonin Antagonists; Serotonin Receptor Agonists | 2000 |